Novascreen (Bioscrine)

History and Performance Indicators

2023: Joining the KDL network of laboratories

Novascreen laboratories have become part of the federal network of KDL laboratories and will continue to operate under the KDL brand. This information is published on the Novascreen website. Vedomosti announced the deal of the parties at the end of April 2023. According to market sources, the deal has not yet been legally closed. Its conditions and structure are not disclosed.

As of the end of April 2023, the Novascreen network included 55 medical offices in Moscow. According to SPARK, it belonged to the Ogment Investment Limited company Viktor Kharitonin and Yegor Kulkov, which owns assets such as Pharmstandard and MedInvestGroup.

Analysts estimated the market value of Novascreen at 300-350 million rubles.

The KDL network at the time of the transaction included 13 regional laboratories and over 350 medical offices in 40 cities of Russia.^[1] At the end of 2022, the KDL network was acquired by Medskan from the UFG Private Equity private equity fund.

2021:65% reduction in net loss

The net loss of JSC Bioskrin, which manages the laboratories of this network, in 2021 amounted to 68.8 million rubles, in 2022 the figure decreased by 65% to 24.5 million rubles.

Notes